Searched for
NIVOLUMAB
Rs 1 lakh to Rs 30,000: Cancer immunotherapy gets cheaper, but will patients get the price benefit?Cheaper nivolumab biosimilars are expanding access to cancer immunotherapy in India, with one Mumbai oncologist reporting a more than 50% r...- Dr Reddy’s Q2 Results: Net profit falls 36% YoY to Rs 913 crore, revenue declines marginallyDr Reddy’s Laboratories reported a 36% year-on-year profit decline to Rs 913.4 crore in Q2 FY27, while revenue slipped 1.5%. North America ...
- Zydus gearing up for next phase of growth, eyeing new areas: Sharvil Patel, MD"From 2030 and beyond, we will see strong earnings from pure discovery-led business, which is our central business, our oncology business a...
- Dr. Reddy's launches nivolumab biosimilar in IndiaDr Reddy's Laboratories has taken a significant step in cancer care with the introduction of NIVORZ, a biosimilar of nivolumab. Designed to...
- Chinese medicines bring relief to India’s cancer patientsIndia’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...
- Zydus Life cleared to sell life-saving cancer drug; SC tells Bristol Myers to map patentsThe Supreme Court has provided Zydus Lifesciences with the go-ahead to launch its cancer drug biosimilar, countering efforts by Bristol Mye...
- Bristol Myers moves SC to stop Zydus from selling biosimilar cancer drugUS firm Bristol Myers Squibb is in the Supreme Court seeking to halt Zydus Lifesciences from manufacturing and selling a biosimilar cancer ...
- Zydus Lifesciences launches world's first nivolumab biosimilar in India, boosting cancer treatment affordabilityAhmedabad-based Zydus Lifesciences has launched Tishtha, the world's first biosimilar of the oncology drug nivolumab, in India. This move s...
- Zydus launches biosimilar for treatment of multiple cancersZydus Lifesciences has launched Tishtha, the world's first biosimilar of Nivolumab, in India. This drug treats multiple cancers. Tishtha wi...
- Delhi HC clears Zydus to sell biosimilar of BMS cancer drug NivolumabThe Delhi High Court has permitted Zydus Lifesciences to produce and market a biosimilar cancer drug. This decision comes as the patent for...
- Biocon Biologics to introduce three new biosimilars for cancer treatmentBiocon Biologics will launch three new oncology biosimilars. These include Trastuzumab/Hyaluronidase, Nivolumab, and Pembrolizumab. The com...
- Zydus moves Delhi HC against order restraining manufacture, sale of its cancer drugZydus Lifesciences has appealed a Delhi High Court order. The order restricts it from producing a biosimilar of E.R. Squibb's Nivolumab. Sq...
- Zydus Life's plans for cancer biosimilar hit a legal hurdleThe Delhi High Court has granted an interim injunction against Zydus Lifesciences, an Ahmedabad-based drug maker, following a patent infrin...
- No April Fool's joke: New Zealand hikes benefits, minimum wage and healthcare funding from April 1New Zealand will implement changes from April 1, 2025, affecting benefits, minimum wage, power prices, student loan repayments, and Pharmac...
- Cancer drugmaker Bristol Myers to build its largest R&D facility outside US in India by 2025The $100-million facility, inaugurated by Boerner on Monday, is expected to employ over 1,500 employees and will be used to enhance its dru...
- Top cancer drugs may come under price controlTaking cue from the WHO’s revised list of essential medicines, popular biosimilars for cancer cure may get incorporated in India’s revised ...
- World Cancer Day: Immunotherapy can help patients suffering from carcinoma of the lungsImmunotherapy should be given as early as possible to achieve a lasting remission of the disease.
- New immunotherapy for lung cancer may be effective, safe: LancetNew York, April 8 (IANS) A novel immunotherapy combination is effective and safe at controlling the progression of lung cancer, results fro...
- Medical breakthrough! Aurigene closer to developing cancer treatment capsuleThe Bengaluru-based company is an independent subsidiary of Dr Reddy’s Laboratories and its United States-based partner Curis Inc.
- We are beginning to treat cancer in a whole new way: ScientistsRather than killing cancer cells directly with chemo , the latest treatments are designed to promote the body's natural immune control over...
Load More
